Glenmark Pharmaceuticals Limited — research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Glenmark Pharmaceuticals Limited, explained in plain English.

• ▪Glenmark Pharmaceuticals Limited is tracked in the Pharma & Healthcare sector of our NSE large-cap universe.
• ▪Reported fundamentals show a net margin of 10.14%, debt to equity of 5.65.
• ▪Our transparent MaxGrade checklist scores it C (56/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 26.99% with a maximum drawdown of -11.63% and a beta of 0.86 against NIFTY 50.

Figures from the current session. Market open.